Novartis Ag (NVS) Deferred Taxes (2018 - 2019)
Novartis Ag's (NVS) quarterly Deferred Taxes came in at $33.0 billion in Q4 2019, down 24.79% year-over-year from $43.9 billion in Q4 2018, and down 24.79% quarter-over-quarter from $43.9 billion in Q4 2018.
Powered by 
Analysis
Novartis Ag (NVS) Deferred Taxes (2018 - 2019) Analysis & Trends
Novartis Ag has disclosed Deferred Taxes across 2 years of filings, most recently posting $33.0 billion for Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | -479.00 Mn |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | -195.00 Mn |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | -544.00 Mn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | - |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | -1.32 Bn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | - |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | 115.62 Mn |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | 25.70 Mn |
| 10 | Neurocrine Biosciences | 15.82 Bn | 15.43 Bn | 935.80 Mn | -25.30 Mn |